Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study - Wikidata - awgldk - TriplyDB

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

http://www.wikidata.org/entity/Q36043066

about

Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Novel Drugs in Follicular Lymphoma When to treat patients with relapsed follicular lymphoma.HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Immune checkpoint blockade for hematologic malignancies: a review Checkpoint inhibitors in hematological malignancies Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis.Cancer immunotherapies targeting the PD-1 signaling pathway.Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.Novel Immunotherapies for Multiple Myeloma.Therapeutic Options for Aggressive T-Cell Lymphomas.Mechanisms of Immune Tolerance in Leukemia and Lymphoma.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Immunologic approaches for the treatment of multiple myeloma.The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report.Emerging role of checkpoint blockade therapy in lymphoma.PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.How is patient care for multiple myeloma advancing?The emerging role of immune checkpoint inhibition in malignant lymphoma.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Novel treatment concepts in Hodgkin lymphoma.Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.The landscape of new drugs in lymphoma Is immunotherapy here to stay in multiple myeloma?Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression New monoclonal antibodies on the horizon in multiple myeloma Targeting the programmed death-1 pathway in lymphoid neoplasms.

P2860

Q28067817-F1DA7E72-A5AE-4912-9283-6590B927E28D Q28076335-548C61D2-FACF-47A3-9A67-64BC00DAA1BD Q30238528-E8CB241F-A1AA-46DB-A26B-11948FDDA1B5 Q33632104-F72A8FF9-AC74-4BF5-8DF8-74896A2ADEE1 Q33638083-A2806F46-07C2-4456-ABC2-CA279700DACA Q33645590-4402A28A-1428-4683-A124-F8D0F511C60B Q33651495-2A914CE4-BB6E-49A8-A319-5E2C458ACBB6 Q33823259-6264ACF0-2DA3-49F4-B324-5EB24974AE8F Q36372043-887F1B2E-4264-4524-A89D-0F1959232D75 Q37390723-3785F712-29F4-4C3D-B0BB-3BE08C027661 Q37517482-F4C57BB6-8D24-4E59-9652-375FD3678F02 Q37589557-9FDD80CC-56AE-42A6-AA83-91E5E12F1FAC Q37653011-5B03C147-BD9F-4855-A157-6670E89A32FD Q37737940-72BE1520-6A59-4AF2-BC5B-EF60B12AF607 Q38402634-55E7163C-25B7-4205-BB56-6D13C05EA5D9 Q38640444-E8E99CE7-7D13-41B5-AAEB-C8CE3E1EE47F Q38675843-9D7FE658-7A97-4DF5-98E4-4BFE86286D95 Q38683034-DF59F29F-D884-41CE-A530-A3CC440D13A5 Q38685006-92D62CF2-C38D-4F60-8A5D-7BBAE5D5368C Q38692244-E363754A-FBC1-475E-B021-367D7CF5F262 Q38729502-0FA06525-7BE0-4F53-9EC2-04F8EA731808 Q38741324-06AEBB09-1A8B-4E10-A187-35A7E234C760 Q38756923-7AFB64FC-5250-490F-9EC1-675C51783912 Q38765760-B7A6A122-8F41-4009-A938-2DC29EBCE4A5 Q38765889-228ECB02-C5F4-4E1A-972A-5852799651E2 Q38782072-E87B74EF-CA25-4A8D-8F0D-9BD0175C1DA2 Q38786149-4E8B2D7E-EF9A-4C1D-9F0D-648CE4D8C507 Q38791036-E115A541-80D5-4270-B36B-3CC04D6A729E Q38996724-0FEFF8EB-C94D-4239-B03D-9339A1A94468 Q39039017-669654FE-B5DD-48BC-965C-7CF787D09318 Q39043082-8C8893A1-1BDC-4992-890C-F8A605C3E797 Q39055861-75C6A0C4-3ED3-42E7-BB89-BB916CA46297 Q39061630-46C0964B-758D-48DC-B785-BF5A97633665 Q39084427-B8689A2F-9CC4-4C52-88F9-0B3CB1FA8A9F Q39091822-206F8920-D4CE-4329-8865-ED81C9BFEE8B Q39093915-37808C59-5490-42B2-AEE1-AC2B2C87CF5B Q39116985-C245B6C4-F90D-4827-AE0C-87B5077F55A4 Q39136762-94A7EED0-14F9-4FFD-BEA0-80346E8571F6 Q39137696-2B0E78C8-E298-4103-830F-B9C0E8694218 Q39153358-6B4BFF6A-C443-421B-AACA-8CD51CD0AE0E

P2860

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

http://www.wikidata.org/entity/Q36043066

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Nivolumab in Patients With Rel ...... ry Results of a Phase Ib Study

@ast

Nivolumab in Patients With Rel ...... ry Results of a Phase Ib Study

@en

type

label

Nivolumab in Patients With Rel ...... ry Results of a Phase Ib Study

@ast

Nivolumab in Patients With Rel ...... ry Results of a Phase Ib Study

@en

prefLabel

Nivolumab in Patients With Rel ...... ry Results of a Phase Ib Study

@ast

Nivolumab in Patients With Rel ...... ry Results of a Phase Ib Study

@en

P1433

Q36043066-7B2F73D5-B35D-4613-86D5-5A7CA4ABA19C

P1476

Q36043066-D4460094-48FC-4A76-AFCC-7B2F7155D37D

P2093

Q36043066-141B6BCE-D7F1-4CD7-A42D-8FDEC014C032

Q36043066-185260E2-6BB6-4C27-BEA2-5935F5ED5456

Q36043066-24147536-C7BF-4698-B358-A72B91DB296C

Q36043066-2D725CBA-E5CD-4F60-BC88-21A28F3D8CED

Q36043066-31A12B7C-4ECD-4A65-8049-EA785037A82F

Q36043066-412C0D6A-5F81-4DCE-AADD-076103DF0578

Q36043066-61A9BC73-7DC5-4CD9-8518-DA05F1B52E1B

Q36043066-6F570D81-C373-46E6-B979-9A927C8766B9

Q36043066-74DB16B4-B6B0-40CC-BEB1-E648BC73FF56

Q36043066-7525BD47-93B1-41EE-B7E5-7FB0F858D079

P2860

Q36043066-0CD2B634-EBB6-4B5C-843C-D3B0B4CE7D33

Q36043066-120AE35E-4B5E-43CA-B377-5EC317DF003C

Q36043066-1575CDB7-E795-4785-81A0-E8B84616D730

Q36043066-17318125-302B-4B87-BC16-ACBDC896DEF2

Q36043066-19CC693A-81F7-49FF-ACF2-690BC876CF42

Q36043066-4A6682A2-57A4-4A81-9056-4A70ADEAFCD8

Q36043066-4FF9688A-89FC-4806-9A9C-843B91F3FF49

Q36043066-6801A7AB-457B-458D-A701-11FEB1FAFF29

Q36043066-6F0C9D36-9877-4781-9573-09A85EA8C6F8

Q36043066-767C1D8D-F4A6-481D-BCE4-A7B555135E86

P304

Q36043066-DA7CACBD-8298-4183-9D13-1CBCF439A32A

P31

Q36043066-720A1722-2AA9-4B54-9CFE-8FAFA23E8935

P356

Q36043066-48E9F734-5E36-4328-8353-351CA81BF2CA

P407

Q36043066-82CD54E2-CABC-45C6-A32C-527A932E93C4

P433

Q36043066-0061E70E-CCF6-4AA9-9E66-1D5C2DAD5028

P478

Q36043066-20CED998-7D4F-4C3A-85A5-92AB20ABDFAB

P50

Q36043066-430A77D9-57A9-4AF9-AE81-DE04FD5E6FBE

P577

Q36043066-37E70587-4729-4081-87FE-75711BF5F0EF

P698

Q36043066-751D2029-D617-47E3-B7F9-712F8E7C1E67

P932

Q36043066-74389CCE-2BBF-4B6A-96BB-9158D98449F3

P356

JCO.2015.65.9789

P1433

Journal of Clinical Oncology

P1476

Nivolumab in Patients With Rel ...... ry Results of a Phase Ib Study

@en

P2093

Ahmad Halwani

http://www.w3.org/2001/XMLSchema#string

Alexander M Lesokhin

http://www.w3.org/2001/XMLSchema#string

Azra H Ligon

http://www.w3.org/2001/XMLSchema#string

Bjoern Chapuy

http://www.w3.org/2001/XMLSchema#string

Daniel Lebovic

http://www.w3.org/2001/XMLSchema#string

David Avigan

http://www.w3.org/2001/XMLSchema#string

Deepika Cattry

http://www.w3.org/2001/XMLSchema#string

Emma C Scott

http://www.w3.org/2001/XMLSchema#string

Gordon J Freeman

http://www.w3.org/2001/XMLSchema#string

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Nivolumab plus ipilimumab in advanced melanoma.

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Immunologic correlates of the abscopal effect in a patient with melanoma

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

P304

2698-2704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.65.9789

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27269947

http://www.w3.org/2001/XMLSchema#string

P932

5019749

http://www.w3.org/2001/XMLSchema#string